Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The increasing success of intensive consolidation chemotherapy (CCT) as an alternative to bone marrow transplant (BMT) in acute myeloid leukaemia (AML) necessitates comparison of the impact on quality of life (QoL) of these two treatment modalities. Most QoL studies following BMT involve small patient numbers and provide ambivalent results. The present study examines QoL in a large number of patients 1 year from the end of treatment within the United Kingdom Medical Research Council (UK MRC) AML10 trial of BMT versus CCT. Allogeneic-BMT (Allo-BMT) was observed to have an adverse impact on most QoL dimensions compared with Autologous-BMT (A-BMT) and CCT. More patients receiving BMT had mouth dryness problems and worse sexual and social relationships, professional and leisure activities than CCT patients. QoL in A-BMT patients was less impacted than Allo-BMT. Intention-to-treat analysis showed similar results. These results indicate that a reconsideration of treatment strategies is warranted, and that further, good prospective studies are needed to evaluate more clearly the effects of these treatments in long-term survivors.

Original publication

DOI

10.1016/S0959-8049(03)00628-2

Type

Journal article

Journal

Eur J Cancer

Publication Date

05/2004

Volume

40

Pages

971 - 978

Keywords

Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Transplantation, Cognition Disorders, Cost of Illness, Fatigue, Female, Graft vs Host Disease, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Transplantation, Homologous